Compare
Perrigo Co PLC vs Jazz Pharmaceuticals plc vs Alnylam Pharmaceuticals, Inc. vs BeOne Medicines Ltd.
| Latest fiscal year | Perrigo Co PLC PRGO | Jazz Pharmaceuticals plc JAZZ | Alnylam Pharmaceuticals, Inc. ALNY | BeOne Medicines Ltd. ONC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.25B | $4.27B | $3.71B | $5.34B |
| Revenue growth (YoY) | -2.8% | +4.9% | +65.2% | +40.2% |
| Gross margin | 35.1% | n/a | 81.8% (computed) | 87.5% |
| Operating margin | -26.4% | -10.1% | 13.5% | 8.4% |
| Net margin | -33.5% | -8.3% | 8.4% | 5.4% |
| Net income | -$1.43B | -$356.15M | $313.75M | $286.93M |
| EPS (Diluted) | -$10.29 | -$5.84 | $2.33 | $0.19 |
| Operating cash flow | $238.50M | $1.36B | $524.08M | $1.13B |
| Free cash flow | $145.10M | $1.30B | $465.38M | $941.74M |
| Cash & equivalents | n/a | $1.39B | $1.66B | $4.55B |
| Total assets | $8.54B | $11.66B | $4.97B | $8.19B |
| Total liabilities | $5.60B | n/a | $4.18B | $3.83B |
| Shareholders' equity | $2.94B | $4.32B | $789.18M | $4.36B |
| Return on year-end equity | -48.6% | -8.2% | 39.8% | 6.6% |
| Shares outstanding | 137.60M | 61.44M | 132.38M | 1.44B |
Revenue, most recent five fiscal years
| Fiscal year | Perrigo Co PLC | Jazz Pharmaceuticals plc | Alnylam Pharmaceuticals, Inc. | BeOne Medicines Ltd. |
|---|---|---|---|---|
| Latest | $4.25B Ended 2025-12-31 | $4.27B Ended 2025-12-31 | $3.71B Ended 2025-12-31 | $5.34B Ended 2025-12-31 |
| 1 year earlier | $4.37B Ended 2024-12-31 | $4.07B Ended 2024-12-31 | $2.25B Ended 2024-12-31 | $3.81B Ended 2024-12-31 |
| 2 years earlier | $4.66B Ended 2023-12-31 | $3.83B Ended 2023-12-31 | $1.83B Ended 2023-12-31 | $2.46B Ended 2023-12-31 |
| 3 years earlier | $4.45B Ended 2022-12-31 | $3.66B Ended 2022-12-31 | $1.04B Ended 2022-12-31 | $1.42B Ended 2022-12-31 |
| 4 years earlier | $4.14B Ended 2021-12-31 | $3.09B Ended 2021-12-31 | $844.29M Ended 2021-12-31 | $1.18B Ended 2021-12-31 |